Comparing two chemotherapies after pancreatic cancer surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial compares two chemotherapy combinations given after surgery to prevent pancreatic cancer from returning. One group gets the study drug HR070803 plus oxaliplatin and S-1, while the other gets a standard regimen called NALIRIFOX.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had surgery to completely remove pancreatic cancer (R0 or R1 resection).
- You are up and about (ECOG score 0 or 1).
- Your life expectancy is at least 6 months.
- You are ready to start treatment between 3 and 12 weeks after surgery.
- At least 15 lymph nodes were removed during surgery.
- Your CA19-9 blood test is within normal range and you have not had prior chemotherapy or radiation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new chemotherapy combination (HR070803 plus two other drugs) given after surgery to see if it prevents pancreatic cancer from coming back better than the current standard treatment.
This study compares two chemotherapy strategies for people with advanced pancreatic cancer who have not yet had treatment. The goal is to see if switching to a different chemotherapy combination (gemcitabine plus nab-paclitaxel) after initial treatment works better than staying on the original chemotherapy (modified FOLFIRINOX).
This clinical trial tests whether a combination of chemotherapy drugs (liposomal irinotecan, oxaliplatin, and S-1) is more effective than another standard chemotherapy combination (gemcitabine plus capecitabine) after surgery for pancreatic cancer. It aims to help prevent the cancer from coming back.
This trial tests a combination of chemotherapy drugs (NALIRIFOX) given before and after surgery for people with pancreatic cancer that is at high risk of coming back but can still be surgically removed. The goal is to see if this treatment helps improve outcomes.
This study compares two chemotherapy combinations for people with advanced (locally advanced or metastatic) pancreatic cancer that hasn't been treated yet. The goal is to see which combination works better and has fewer side effects.
This Phase 2 study compares two chemotherapy combinations to treat metastatic pancreatic cancer that has progressed after gemcitabine (with or without Abraxane). It aims to see which combination works better and is tolerable for people with measurable disease.
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.